Abstract
Progress in the field of NK cell receptors (NKRs) and their ligands has revolutionized our concept of how NK cells selectively recognize and lyse tumor while sparing normal cells. Major families of NKRs that inhibit and activate NK cells to lyse target cells have been characterized, including killer cell immunoglobulin-like receptors (KIRs), C-type lectins, and natural cytotoxicity receptors. Identification of NK receptor ligands such as HLA, MHC class I chain-related genes A and B – MICA/B, etc. further clarifies the role of NKR/ligand interactions in NK cell function. Given the extensive genomic diversity of KIRs, HLA and MIC, it is reasonable to imagine that genotypes encoding imbalanced inhibitory and activating interactions may contribute to susceptibility or resistance to human diseases, including cancers. This review will discuss two cell-surface receptor/ligand systems involved in NK cell recognition of tumor targets – KIR/HLA and NKG2D/MIC and the potential relevance of their genetic polymorphism in malignancies.
Keywords: NK cell receptors, NK receptor ligands, polymorphism, malignancies
Current Cancer Therapy Reviews
Title: NK Cell Receptor and MHC Gene Polymorphisms, Potential Relevance in Malignancies
Volume: 4 Issue: 2
Author(s): Anastassia Mihaylova, Snejina Mihailova and Elissaveta Naumova
Affiliation:
Keywords: NK cell receptors, NK receptor ligands, polymorphism, malignancies
Abstract: Progress in the field of NK cell receptors (NKRs) and their ligands has revolutionized our concept of how NK cells selectively recognize and lyse tumor while sparing normal cells. Major families of NKRs that inhibit and activate NK cells to lyse target cells have been characterized, including killer cell immunoglobulin-like receptors (KIRs), C-type lectins, and natural cytotoxicity receptors. Identification of NK receptor ligands such as HLA, MHC class I chain-related genes A and B – MICA/B, etc. further clarifies the role of NKR/ligand interactions in NK cell function. Given the extensive genomic diversity of KIRs, HLA and MIC, it is reasonable to imagine that genotypes encoding imbalanced inhibitory and activating interactions may contribute to susceptibility or resistance to human diseases, including cancers. This review will discuss two cell-surface receptor/ligand systems involved in NK cell recognition of tumor targets – KIR/HLA and NKG2D/MIC and the potential relevance of their genetic polymorphism in malignancies.
Export Options
About this article
Cite this article as:
Mihaylova Anastassia, Mihailova Snejina and Naumova Elissaveta, NK Cell Receptor and MHC Gene Polymorphisms, Potential Relevance in Malignancies, Current Cancer Therapy Reviews 2008; 4 (2) . https://dx.doi.org/10.2174/157339408784310070
DOI https://dx.doi.org/10.2174/157339408784310070 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Impact of Curcumin on Microsomal Enzyme Activities: Drug Interaction and Chemopreventive Studies
Current Medicinal Chemistry Melatonin in the Biliary Tract and Liver: Health Implications
Current Pharmaceutical Design Three Amino Acid Derivatives of Valproic Acid: Design, Synthesis, Theoretical and Experimental Evaluation as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Texaphyrins: Tumor Localizing Redox Active Expanded Porphyrins
Anti-Cancer Agents in Medicinal Chemistry New Uses of Melatonin as a Drug; A Review
Current Medicinal Chemistry Design, Development and Characterization of Topical Microemulsions of 5-Fluorouracil for the Treatment of Non Melanoma Skin Cancer and its Precursor Lesions.
Anti-Cancer Agents in Medicinal Chemistry Small Regulatory Molecules Acting Big in Cancer: Potential Role of Mito-miRs in Cancer
Current Molecular Medicine Anti-Tumorigenic Effects of Resveratrol in Lung Cancer Cells Through Modulation of c-FLIP
Current Cancer Drug Targets Reversal of Resistance to Oxazaphosphorines
Current Cancer Drug Targets Toll-Like Receptors: Cost or Benefit for Cancer?
Current Pharmaceutical Design Allelic Variations in CYP2D6 Gene and Susceptibility to Cervical Cancer
Drug Metabolism Letters Epigenetic Modifications in Acute Lymphoblastic Leukemia: From Cellular Mechanisms to Therapeutics
Current Gene Therapy Green Tea Polyphenols as Proteasome Inhibitors: Implication in Chemoprevention
Current Cancer Drug Targets Targeting Anti-Cancer Active Compounds: Affinity-Based Chromatographic Assays
Current Pharmaceutical Design ABC Transporters: Unvalidated Therapeutic Targets in Cancer and the CNS
Anti-Cancer Agents in Medicinal Chemistry Is There an Increased Risk of Lymphoma and Malignancies Under Anti- TNF Therapy in IBD?
Current Drug Targets UBE2L6 is Involved in Cisplatin Resistance by Regulating the Transcription of ABCB6
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in Research on the Most Novel Carbonic Anhydrases,CA XIII and XV
Current Pharmaceutical Design Anti-cancer Effects of Metformin: Recent Evidences for its Role in Prevention and Treatment of Cancer
Current Drug Metabolism Long Noncoding RNA MALAT1: Insights into its Biogenesis and Implications in Human Disease
Current Pharmaceutical Design